Parkinson's disease: pathological mechanisms and actions of piribedil Peter Jenner OriginalPaper Pages: S2 - S8
Deterioration of dopaminergic pathways and alterations in cognition and motor functions B. DuboisB. PillonY. Agid OriginalPaper Pages: S9 - S12
Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil Hélène Ollat OriginalPaper Pages: S13 - S16
Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil P. LapalusP. DenisP. P. Elena OriginalPaper Pages: S17 - S21
Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects C. CorbeF. ArnaudC. Janiak-Bolzinger OriginalPaper Pages: S22 - S27
Activity and acceptability of piribedil in Parkinson's disease: a multicentre study P. RondotM. Ziegler OriginalPaper Pages: S28 - S34